The financing de-risks Achieve’s path to commercialization with substantial near-term capital and contingent upside. Traders should monitor FDA action on cytisinicline by the PDUFA date of June 20, 2026, as warrant exercise and additional funding depend on approval. The leadership change signals strategic focus on commercial readiness.
Price Chart
Executive Summary
Achieve Life Sciences announced a $354 million private placement financing, including $180 million upfront and up to $174 million from milestone-driven warrants exercisable upon FDA approval of cytisinicline. The deal is led by prominent healthcare investors and includes a leadership change, with Dr. Andrew D. Goldberg appointed CEO effective post-closing.
Key Financial Metrics
Key Facts
- Private placement raises up to $354 million in gross proceeds, with $180 million upfront and up to $174 million from warrants tied to FDA approval.
- Warrants exercisable only after FDA approval of cytisinicline for smoking cessation, creating a milestone-driven capital structure.
- Leadership transition: Dr. Andrew D. Goldberg appointed CEO; current CEO Richard Stewart remains on board.
- Proceeds to fund Phase 3 trial for e-cigarette cessation, commercialization efforts, and general corporate purposes.
- Morgan Stanley acting as sole placement agent; registration statement to be filed within 30 days of closing.
Financial Impact
Approximately $354 million in gross proceeds, with $180 million immediately available and potential for additional $174 million upon FDA approval.
Risk Factors
- FDA may not approve cytisinicline by the PDUFA date of June 20, 2026, limiting access to the second tranche of funding.
- Significant shareholder dilution from issuance of nearly 50 million shares and pre-funded warrants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275382 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.49 (−10.36%) |
Oct 1, 2026 24d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.49 (−10.36%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.49 (+13.47%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.49 (−2.99%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.49 (+4.14%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.49 (−2.41%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.49 (−17.57%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.49 (+29.03%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.49 (−38.38%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.49 (+45.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers